Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business Updates

ET to report financial results for the second quarter ended June 30, 2019 and provide business updates.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, August 1, 2019

Information

Tags:

Lung cancer, Cancer, Gynaecological cancer, Neoplasms, Health, Gynaecology, Oncology, Ovarian cancer, RTT, Non-small-cell lung carcinoma

Geotags:

Cambridge, Ma, Us

Organisation:

MERSANA THERAPEUTICS, INC.

Summary

Key Points:

ET to report financial results for the second quarter ended June 30, 2019 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5554418.
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
Mersanas lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers.

CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Thursday, August 8, 2019 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2019 and provide business updates.

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5554418. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to cancer patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody, 617-844-8577
[email protected]